In 2026, the adjustment of the medical insurance directory will add pre-declaration, allowing commercial insurance to apply for innovative drugs to be included in the medical insurance directory.

The State Medical Insurance Administration introduced the work arrangement for the adjustment of the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List for 2026, including allowing drugs listed in the 2025 Commercial Insurance Innovative Drug List to apply for inclusion in the National Medical Insurance List for the first time, and adding a "pre-application" process. Huang Xinyu, Director of the Pharmaceutical Service Management Department of the State Medical Insurance Administration, stated that this is the 9th consecutive year of dynamic adjustment of the medical insurance list since the establishment of the agency. The overall work procedure remains stable and is divided into five stages: preparation, application, review, negotiation, and announcement of results. It is expected that by the end of this month, the work plan for the adjustment of the 2026 National Medical Insurance List and the Commercial Health Insurance Innovative Drug List will be released. The two new versions of the list will be published by the end of November.